Increased exposure of BCRP substrates eg, rosuvastatin. Decreased plasma conc w/ strong (eg, carbamazepine, phenobarb, phenytoin, rifampicin, rifabutin, St. John's wort) & moderate (eg, oxcarbazepine, rifapentine) P-gp inducers. Changes in liver function w/ vit K antagonists. Decreased conc w/ medicinal products increasing gastric pH eg, antacids, H2
-receptor antagonists. Increased conc of rosuvastatin, simvastatin, atorvastatin, fluvastatin. Caution w/ digoxin, dabigatran etexilate, pravastatin, pitavastatin.